Acasti to Attend HC Wainwright 26th Annual Global Investment Conference Page 1

PRINCETON, N.J., Sept. 5, 2024 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage biopharmaceutical company developing GTX-104, its novel injectable formulation of nimodipine that addresses the high unmet medical need for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company will participate in HC Wainwright’s 26th Annual Global Investment Conferencewhich will be held in New York, NY from September 9 to 11.

Prashant Kohli, Chief Executive Officer of Acasti, will be available for one-on-one discussions on September 9^and and 10^and.